S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
NASDAQ:EGRX

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

$5.14
+0.13 (+2.59%)
(As of 01:05 PM ET)
Today's Range
$4.96
$5.23
50-Day Range
$4.42
$6.51
52-Week Range
$4.10
$32.44
Volume
19,596 shs
Average Volume
230,806 shs
Market Capitalization
$66.77 million
P/E Ratio
4.36
Dividend Yield
N/A
Price Target
$17.00

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
226.9% Upside
$17.00 Price Target
Short Interest
Bearish
10.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.02 out of 5 stars

Medical Sector

213th out of 939 stocks

Pharmaceutical Preparations Industry

90th out of 433 stocks

EGRX stock logo

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

EGRX Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Eagle Pharmaceuticals Inc (EGRX)
Eagle Pharmaceuticals Deadline Reminder
See More Headlines
Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
134
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+226.9%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$35.64 million
Pretax Margin
11.33%

Debt

Sales & Book Value

Annual Sales
$316.61 million
Cash Flow
$3.91 per share
Book Value
$17.94 per share

Miscellaneous

Free Float
9,234,000
Market Cap
$67.55 million
Optionable
Optionable
Beta
0.42

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael Graves (Age 61)
    Interim Principal Executive Officer & Executive Chairman of the Board
    Comp: $160k
  • Mr. Steven B. Ratoff (Age 81)
    Independent Director & Interim Chief Financial Officer
    Comp: $100k
  • Mr. Ryan Debski
    Executive VP, General Counsel & Chief Compliance Officer
  • Mr. Daniel O'Connor (Age 44)
    Executive VP, Chief Strategy Officer & Head of Corporate Development
  • Dr. Valentin R. Curt M.D.
    Senior Vice President of Clinical Drug Development
  • Dr. Gaozhong Zhu Ph.D.
    Senior Vice President of Pharmaceutical Development
  • Ms. Debra M. Hussain
    Senior VP & Head of Commercial
  • Mr. Reed McClung
    Executive Vice President of Oncology Business Development

EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings
or view top-rated stocks.

What is Eagle Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 12 month target prices for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 226.9% from the stock's current price.
View analysts price targets for EGRX
or view top-rated stocks among Wall Street analysts.

How have EGRX shares performed in 2024?

Eagle Pharmaceuticals' stock was trading at $5.23 at the beginning of 2024. Since then, EGRX stock has decreased by 0.6% and is now trading at $5.20.
View the best growth stocks for 2024 here
.

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our EGRX earnings forecast
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analyst estimates of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same period in the previous year, the company posted $0.51 EPS.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (5.74%), Vanguard Group Inc. (4.91%), Vanguard Group Inc. (4.91%), LSV Asset Management (3.02%), Dimensional Fund Advisors LP (1.90%) and Goldman Sachs Group Inc. (1.49%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends
.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners